The FDA Is Finally Asking the Public What It Thinks About Psychedelic Therapy. That Question Was Illegal to Even Study for 40 Years.

On September 14, in a federal building in the D.C. area, the FDA will spend four hours listening to public testimony on a question that was, for four decades, not a question anyone in the U.S. government was legally allowed to fund research into: does a mushroom-derived compound, given once or twice under clinical supervision, belong in medicine? The hearing itself is the story before a single word of testimony is given — because the fact that the FDA is asking is the most concrete sign yet that psilocybin’s decades in the wilderness are ending.

Here’s the plain-language version of what’s actually on the table, per the FDA’s own hearing notice: the agency and HHS are gathering public input on how psychedelic drugs — psilocybin (the compound in “magic mushrooms”), MDMA, and LSD chief among them — could someday be used as medicine, always inside a supervised clinical setting, never as a take-home prescription. That last part matters and gets flattened in every headline: nothing being discussed puts psilocybin in your medicine cabinet. What’s being discussed is whether a trained clinician can legally administer it to you in a room built for it, the way an anesthesiologist administers ketamine today.

Why this took forty years, and whose decision that was

To understand why a hearing counts as news, you have to know what came before it. In the late 1960s and into 1970, the federal government moved LSD and psilocybin into Schedule I of the Controlled Substances Act — the category reserved for drugs with, by legal definition, no accepted medical use and high abuse potential. That single classification didn’t just restrict street use. It made government-funded clinical research into these compounds almost impossible to run for the next thirty-plus years, even as a small stream of researchers, mostly at Johns Hopkins and NYU starting in the early 2000s, fought through the regulatory maze to restart human trials from nearly zero. An entire generation of psychiatric researchers who might have studied these compounds spent their careers doing something else, because the law had already decided the answer before the science got a chance to ask the question. That history is why a public hearing — a bureaucratic, unglamorous, four-hour comment session — is being read by the field as a genuinely big deal. It is the government formally reopening a question it spent forty years refusing to entertain.

The vouchers are real. The hype outruns the data.

Underneath the hearing, three companies are already moving through the FDA pipeline with a real regulatory advantage. On April 24, 2026, the FDA awarded three Commissioner’s National Priority Vouchers — a fast-track mechanism that compresses the FDA’s review window to one or two months once a company files — to Compass Pathways (psilocybin, for treatment-resistant depression), Usona Institute (psilocybin, for major depressive disorder), and Transcend Therapeutics (a metabolite related to MDMA, for PTSD). Compass’s COMP360 is the furthest along: its Phase 3 trial enrolled more than 1,000 participants and, according to trade coverage of the filing, produced statistically significant, multi-month improvement in treatment-resistant depression with what the company describes as a generally well-tolerated safety profile. A rolling New Drug Application review is underway now, with final submission expected in the fourth quarter of 2026.

That is a real, verifiable regulatory milestone — the furthest a classic psychedelic has ever gotten toward FDA approval. It is also worth naming what it is not: a guarantee. The FDA rejected a different MDMA-assisted therapy application in 2024 over concerns about how hard it is to run a truly blinded trial when participants can usually tell whether they got the active drug or the placebo — a structural problem the field still hasn’t fully solved, which is part of why the FDA’s new clinical trial guidance exists at all. Reports that a newer LSD-based formulation outperformed the ketamine-derived drug Spravato in trials are circulating in trade press as this piece goes to print; we’re naming that claim here specifically because it has not yet been corroborated by a primary FDA or peer-reviewed source, and a reader deciding how much hope to put in psychedelic medicine deserves to know which claims are load-bearing and which are still just one company’s press cycle.

That is a real, verifiable regulatory milestone — the furthest a classic psychedelic has ever gotten toward FDA approval.

What the mechanism actually is — not the trip, the rewiring

If you’ve watched psilocybin coverage reduce itself to “people trip and feel better,” here’s the part that actually matters clinically: researchers believe the therapeutic effect isn’t really about the hallucinations themselves. It’s about a temporary window of unusual neural flexibility — psychologists sometimes call it the brain’s plasticity window — that opens during and shortly after the dosing session, when thought patterns that have been stuck in a rut for years (the self-critical loop of depression, the same fear response replaying after trauma) become, briefly, easier to interrupt and rewrite with a trained therapist’s help. That’s why every serious protocol pairs the drug with hours of talk therapy before and after the session, not just a pill and a checkout desk. If you’ve ever felt like your own mind was running the same track on a loop no matter what you tried, that’s the specific kind of stuckness this mechanism is aimed at — not intoxication, but a hinge point where the loop can be interrupted by someone trained to help you use it.

None of this changes what’s true for a person in a mental health or substance use crisis right now, in September 2026: none of these treatments exist yet, this hearing and these filings are still months to years from changing what’s available at your pharmacy, and the crisis resources at the bottom of this page are real and available tonight, regardless of what the FDA decides on September 14. The hearing matters because it’s the government admitting, in public, that the forty-year-old answer might have been wrong. It does not matter more than that yet — and the field’s own credibility depends on not pretending otherwise while the data is still rolling in.